Ceder, Sophia http://orcid.org/0000-0002-6195-9288
Eriksson, Sofi E.
Liang, Ying Yu
Cheteh, Emarndeena H.
Zhang, Si Min http://orcid.org/0000-0001-7763-603X
Fujihara, Kenji M. http://orcid.org/0000-0002-8387-4912
Bianchi, Julie http://orcid.org/0000-0001-7958-4261
Bykov, Vladimir J. N. http://orcid.org/0000-0002-7199-8942
Abrahmsen, Lars
Clemons, Nicholas J. http://orcid.org/0000-0001-9283-9978
Nordlund, PĂ€r
Rudd, Sean G. http://orcid.org/0000-0002-4368-3855
Wiman, Klas G. http://orcid.org/0000-0002-7113-524X
Funding for this research was provided by:
Robert Lundbergs Minnesstiftelse
VetenskapsrÄdet (2017-01509)
Cancerfonden (18 0774)
Barncancerfonden (PR2017-0106)
Radiumhemmets Forskningsfonder (171213)
Knut och Alice Wallenbergs Stiftelse
Karolinska Institutet
Article History
Received: 6 May 2021
Revised: 24 June 2021
Accepted: 25 June 2021
First Online: 15 July 2021
Change Date: 3 August 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41419-022-05130-y
Competing interests
: This study was funded in part by Aprea Therapeutics, a company that develops p53-based cancer therapy, including APR-246. K.G.W. and V.J.N.B. are co-founders and shareholders of Aprea Therapeutics; K.G.W. is also a member of its Clinical Advisory Board. K.G.W. and V.J.N.B. have received a salary from Aprea Therapeutics. L.A. is Chief Scientific Officer of Aprea Therapeutics. P.N. is the inventor of the CETSA method, which is patented by Pelago Biosciences AB. P.N. is a member of the Board of Directors and shareholder of Pelago Bioscience AB.
: This study did not require ethical approvals.